Donald W. Northfelt

11.2k total citations
212 papers, 6.0k citations indexed

About

Donald W. Northfelt is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Donald W. Northfelt has authored 212 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Oncology, 50 papers in Cancer Research and 41 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Donald W. Northfelt's work include Cancer Treatment and Pharmacology (35 papers), Breast Cancer Treatment Studies (32 papers) and HER2/EGFR in Cancer Research (25 papers). Donald W. Northfelt is often cited by papers focused on Cancer Treatment and Pharmacology (35 papers), Breast Cancer Treatment Studies (32 papers) and HER2/EGFR in Cancer Research (25 papers). Donald W. Northfelt collaborates with scholars based in United States, United Kingdom and Canada. Donald W. Northfelt's co-authors include Lawrence D. Kaplan, Bruce J. Dezube, Richard D. Mamelok, Barbara A. Pockaj, Alvin E. Friedman‐Kien, James Thommes, Paul A. Volberding, Michael Amantea, Margaret A. Fischl and David H. Henry and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Donald W. Northfelt

206 papers receiving 5.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Donald W. Northfelt United States	43	3.2k	1.4k	1.1k	1.0k	978	212	6.0k
Zhengjia Chen United States	51	3.1k 1.0×	2.4k 1.7×	989 0.9×	604 0.6×	2.5k 2.5×	267	8.3k
Domenica Lorusso Italy	46	3.6k 1.1×	1.5k 1.1×	698 0.6×	766 0.7×	1.2k 1.2×	521	9.7k
Martin N. Raber United States	36	4.3k 1.4×	1.7k 1.2×	1.3k 1.1×	1.3k 1.2×	1.3k 1.4×	86	7.1k
Ann T. Farrell United States	37	2.5k 0.8×	2.8k 2.0×	631 0.6×	632 0.6×	621 0.6×	75	6.7k
Judith R. Kroep Netherlands	45	3.1k 1.0×	1.6k 1.1×	1.5k 1.3×	527 0.5×	1.8k 1.9×	215	7.0k
Susana Banerjee United Kingdom	43	3.6k 1.1×	2.1k 1.5×	1.0k 0.9×	903 0.9×	852 0.9×	307	7.0k
Peter G. Rose United States	54	3.2k 1.0×	1.6k 1.1×	693 0.6×	824 0.8×	1.9k 2.0×	274	12.2k
Claire F. Verschraegen United States	46	3.0k 0.9×	2.0k 1.4×	671 0.6×	378 0.4×	1.5k 1.6×	267	6.9k
Mark F. Brady United States	42	3.7k 1.2×	2.0k 1.4×	1.1k 1.0×	1.4k 1.4×	1.6k 1.7×	111	12.0k
Nicola Silvestris Italy	50	3.7k 1.2×	2.4k 1.7×	1.6k 1.4×	658 0.6×	1.5k 1.5×	319	7.4k

Countries citing papers authored by Donald W. Northfelt

Since Specialization

Citations

This map shows the geographic impact of Donald W. Northfelt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald W. Northfelt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald W. Northfelt more than expected).

Fields of papers citing papers by Donald W. Northfelt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald W. Northfelt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald W. Northfelt. The network helps show where Donald W. Northfelt may publish in the future.

Co-authorship network of co-authors of Donald W. Northfelt

This figure shows the co-authorship network connecting the top 25 collaborators of Donald W. Northfelt. A scholar is included among the top collaborators of Donald W. Northfelt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald W. Northfelt. Donald W. Northfelt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patel, Bhavika, Donald W. Northfelt, Karen S. Anderson, et al.. (2024). Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round. Journal of Clinical Oncology. 42(32). 3826–3836. 10 indexed citations

Haddad, Tufia C., Vera J. Suman, Karthik V. Giridhar, et al.. (2024). Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial. Clinical Cancer Research. 30(15). 3147–3156. 3 indexed citations

Haddad, Tufia C., Vera J. Suman, Karthik V. Giridhar, et al.. (2023). Abstract OT1-04-02: Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early stage breast cancer: A prospective trial. Cancer Research. 83(5_Supplement). OT1–4. 1 indexed citations

Shen, Fei, Guanglong Jiang, Santosh Philips, et al.. (2023). Cytochrome P450 Oxidoreductase ( POR ) Associated with Severe Paclitaxel-Induced Peripheral Neuropathy in Patients of European Ancestry from ECOG-ACRIN E5103. Clinical Cancer Research. 29(13). 2494–2500. 2 indexed citations

Patel, Bhavika, Kay Pepin, Kathy R. Brandt, et al.. (2022). Association of breast cancer risk, density, and stiffness: global tissue stiffness on breast MR elastography (MRE). Breast Cancer Research and Treatment. 194(1). 79–89. 20 indexed citations

Patel, Samir H., et al.. (2020). Understanding American Indian Perceptions Toward Radiation Therapy. Cancer Control. 27(3). 1148381255–1148381255. 9 indexed citations

Afifi, Ahmed, Anas M. Saad, Muneer J. Al‐Husseini, et al.. (2019). Causes of death after breast cancer diagnosis: A US population‐based analysis. Cancer. 126(7). 1559–1567. 127 indexed citations

Norton, Nadine, Kathleen Tenner, Karla V. Ballman, et al.. (2018). Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. Breast Cancer Research. 20(1). 52–52. 11 indexed citations

Henderson, Meredith C., Michael Silver, David E. Reese, et al.. (2018). A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment. Clinical Cancer Research. 25(1). 142–149. 17 indexed citations

10.

Knutson, Keith L., Raphael Clynes, Barath Shreeder, et al.. (2016). Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. Cancer Research. 76(13). 3702–3710. 47 indexed citations

11.

Gradishar, William J., Denise A. Yardley, Rachel M. Layman, et al.. (2015). Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy. Clinical Cancer Research. 22(2). 301–309. 54 indexed citations

12.

Haluska, Paul, Michael E. Menefee, Elizabeth R. Plimack, et al.. (2014). Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 20(18). 4747–4757. 55 indexed citations

13.

Galanis, Evanthia, S. Keith Anderson, Joon H. Uhm, et al.. (2013). Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial. Clinical Cancer Research. 19(17). 4816–4823. 127 indexed citations

14.

Reinholz, Monica M., Kathleen Tenner, David W. Hillman, et al.. (2011). Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437. Clinical Cancer Research. 17(22). 7183–7193. 45 indexed citations

15.

Dueck, Amylou C., Chee-Chee H. Stucky, Richard J. Gray, et al.. (2010). Triple-Negative Breast Cancers: Unique Clinical Presentations and Outcomes. Annals of Surgical Oncology. 17(S3). 384–390. 74 indexed citations

16.

Molina, Julian R., et al.. (2009). Abstract #3602: Ongoing phase 1 study of a novel PARP inhibitor, ABT-888 in combination with temozolamide; Pharmacokinetics, safety and anti-tumor activity. Cancer Research. 69. 3602–3602. 2 indexed citations

17.

Papadopoulos, Kyriakos P., Alain C. Mita, Alejandro D. Ricart, et al.. (2007). Pharmacokinetic findings from the phase I study of Quarfloxin (CX-3543): a protein-rDNA quadruplex inhibitor, in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 6. 10 indexed citations

18.

Pegram, M., Tadeusz Pieńkowski, Donald W. Northfelt, et al.. (2004). Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer. JNCI Journal of the National Cancer Institute. 96(10). 759–769. 202 indexed citations

19.

Northfelt, Donald W., Bruce J. Dezube, James Thommes, et al.. (1998). Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.. Journal of Clinical Oncology. 16(7). 2445–2451. 485 indexed citations

20.

Lalezari, Jacob, Gary N. Holland, Françoise Kramer, et al.. (1998). Randomized, Controlled Study of the Safety and Efficacy of Intravenous Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 17(4). 339–344. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact